Targets › AGXT
2 programs from 2 companies in 3 trials: 2 Phase 1, 1 Phase 2; Genitourinary, Metabolic and endocrine; next expected readout Aug 2027.
Peroxisomal aminotransferase that catalyzes the transamination of glyoxylate to glycine and contributes to the glyoxylate detoxification. Also catalyzes the transamination between L-serine and pyruvate and contributes to gluconeogenesis from the L-serine metabolism. (UniProt, P21549)
Open in Phaseline: the race on AGXT, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| YolTech Therapeutics | YOLT-203 Gene editing therapy for alanine-glyoxylate aminotransferase (AGXT) deficiency | AGXT | Phase 2 | Primary Hyperoxaluria Type 1 | Aug 2027 |
| Arbor Biotechnologies | ABO-101 Gene therapy delivering a functional copy of the AGXT gene to hepatocytes | AGXT | Phase 1 | Primary Hyperoxaluria Type 1 (PH1) | Mar 2029 |
Primary Hyperoxaluria Type 1 (2) Primary Hyperoxaluria Type 1 (PH1) (1)
other (1), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.